Therapeutic effectiveness of interferon-alpha 2b against COVID-19: the Cuban experience

  1. R Pereda
  2. D GonzĂĄlez
  3. HB Rivero
  4. JC Rivero
  5. A PĂ©rez
  6. LR LĂłpez
  7. N Mezquia
  8. R Venegas
  9. JR Betancourt
  10. RE DomĂ­nguez
1 evaluations Published on
Read the full article Related papers
This article on Sciety

Abstract

Background

Effective therapies are needed to control the SARS-Cov-2 infection pandemic and reduce mortality associated with COVID-19. Several clinical studies have provided evidence for the antiviral effects of type I interferons (IFNs) in patients with respiratory coronaviruses. This study assessed the therapeutic efficacy of IFN-α2b in patients infected with SARS-CoV-2 during the first month after the outbreak began in Cuba.

Method

This multicenter prospective observational study was conducted in 16 hospitals in 8 Cuban provinces. Participants were patients with confirmed SARS-CoV-2 infection detected from throat swab specimens by real time RT-PCR who gave informed consent and had no contraindications for IFN treatment. Patients received therapy as per the Cuban COVID protocol, that included a combination of oral antivirals (lopinavir/ritonavir and chloroquine) with intramuscular administration of IFN-α2b (Heberon ® Alpha R, Center for Genetic Engineering and Biotechnology, Havana), 3 times per week, for 2 weeks. The primary endpoint was the proportion of patients discharged from hospital (without clinical and radiological symptoms and non-detectable virus by RT-PCR). The secondary endpoint was the case fatality rate (CFR), defined as the number of confirmed deaths divided by the number of confirmed cases.

Results

From March 11 th to April 14 th , 814 patients were confirmed SARS-CoV-2 positive in Cuba, 761 (93.4%) were treated with Heberon ® Alpha R and 53 received the approved protocol without IFN treatment. The proportion of fully recovered patients was higher in the IFN-treated compared with non-IFN treated group (95.4% vs 26.1%, p <0.01). The CFR for all patients was 2.95%, and for those patients who received IFN-α2b the CFR was reduce to 0.92. The estimated global CFR is 6.34% and 4.05% for the Americas reported by WHO and PAHO, respectively. In this study, 82 patients (10.1%) required intensive care and, of these, 42 (5.5%) were treated with IFN.

Conclusions

This report provides preliminary evidence for the therapeutic effectiveness of IFNα-2b for COVID-19 and suggests that the use of Heberon ® Alpha R may contribute to complete recovery.

Related articles

Related articles are currently not available for this article.